Resonance Health Limited (RHT.AX)
- Previous Close
0.0850 - Open
0.0850 - Bid 0.0800 x 6579900
- Ask 0.0850 x 10000000
- Day's Range
0.0810 - 0.0850 - 52 Week Range
0.0370 - 0.0880 - Volume
26,869 - Avg. Volume
228,593 - Market Cap (intraday)
36.198M - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Feb 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in the Asia Pacific, North America, Europe, the Middle East, and Africa. The company offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also provides quantitative imaging measurements and CRO services, such as quality-assured image analysis, project and data management, and issue resolution services; biomarkers, genomics, and laboratory analysis services, as well as works with third party pathology laboratories for blood/sample collection and for standard biochemical/lab safety assessments; design and protocol development, and project management and monitoring services; assessment of subject inclusion or exclusion, evaluating the safety profile of a new therapy, and supporting primary and secondary end-points demonstrating drug efficacy services; and phantoms for the MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.
www.resonancehealth.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: RHT.AX
Performance Overview: RHT.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RHT.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RHT.AX
Valuation Measures
Market Cap
37.99M
Enterprise Value
32.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.74
Price/Book (mrq)
3.86
Enterprise Value/Revenue
5.82
Enterprise Value/EBITDA
-32.14
Financial Highlights
Profitability and Income Statement
Profit Margin
-19.27%
Return on Assets (ttm)
-6.56%
Return on Equity (ttm)
-10.73%
Revenue (ttm)
5.64M
Net Income Avi to Common (ttm)
-1.09M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.9M
Total Debt/Equity (mrq)
3.26%
Levered Free Cash Flow (ttm)
-198.04k